On the stock market since 2017, it operates in the world of health and science. It has 127 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
Average growth of 12% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Cost Efficiency: As sales grow, profit fails to keep the same pace.
An investor who bought at the very peak is down 87% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Sales run at $78.2M a year. A small number, but proof the product has real buyers.
A loss of $21.5M against $78.2M in annual sales.
Over the last 12 months, executives reported 70 sells against just 10 buys. Not an alarm bell by itself, but a number worth watching.
The stock trades 53% above the average analyst price target.
On our five-subject report card, OPTN sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: OPTN is a high-risk stock — not yet profitable, and its future rides on its product catching on.